Global Peptide Synthesis Market Outlook Report Projects $7 Billion by 2035 at 5.2% CAGR Driven by GLP-1 Demand and CDMO Capacity Expansion
Global Peptide Synthesis Market Outlook Report 2026-2035 was published August 31, 2026 via ResearchAndMarkets, projecting global peptide synthesis market growth from $4.4 billion in 2026 to $7.0 billion by 2035 (5.2% CAGR). Growth drivers: growing peptide therapeutics pipeline, rising demand for peptide active pharmaceutical ingredients, continued investment in manufacturing infrastructure, and increased outsourcing to specialized peptide CDMOs. Named anchor programs: CordenPharma more than EUR 900 million capacity investment; PolyPeptide doubling capacity at its Malmö site (in the context of the pending Samsung Biologics acquisition); Cambrex expanding its Waltham, Massachusetts facility. Regulatory context: authorities worldwide have approved nearly 100 peptide-based therapies across cancer, diabetes, chronic pain, HIV, multiple sclerosis, and osteoporosis. Report caveats: the top-line 5.2% CAGR reflects a broad market definition; a narrower peptide CDMO subsegment (Bachem, PolyPeptide, CordenPharma, AmbioPharm) is growing at 20%+ CAGR per multiple industry data sources given the incretin surge.